MarketCap
Madrigal Pharmaceuticals MDGL
$ 432.48
-0.12%
Facebook
X
Telegram
Madrigal Pharmaceuticals EV/EBITDA Ratio | MDGL
Annual EV/EBITDA Ratio Madrigal Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -34.7 | -15.6 | -12.7 | -17.2 | -4.1 | -8.66 | -13.2 | -41 | -52.5 | -2.3 | -0.00752 | -2.43 | -4.16 | -9.82 | -4.74 | -119 | 43.3 | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 43.3 | -119 | -17.6 |
EV/EBITDA Ratio of other stocks in the Biotechnology industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Nektar Therapeutics
NKTR
|
-9.13 | $ 37.82 | -0.01 % | $ 638 M |  USA |
 |
Vaccinex
VCNX
|
-0.372 | - | -61.37 % | $ 654 K | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
-6.09 | - | -19.68 % | $ 18.4 M |  Canada |
 |
Akero Therapeutics
AKRO
|
-10.5 | - | - | $ 3.67 B | USA |
 |
Lineage Cell Therapeutics
LCTX
|
-12.5 | $ 1.05 | -3.24 % | $ 242 M | USA |
 |
Jounce Therapeutics
JNCE
|
1.47 | - | - | $ 98.4 M | USA |
 |
Verona Pharma plc
VRNA
|
-285 | - | - | $ 69.7 B |  Britain |
 |
Corner Growth Acquisition Corp.
COOL
|
-55 | - | -0.89 % | $ 114 M | USA |
 |
Acorda Therapeutics
ACOR
|
0.0567 | - | -24.86 % | $ 820 K | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-8.6 | - | -11.43 % | $ 502 K | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-469 | $ 7.0 | -8.62 % | $ 471 B | Britain |
 |
Mersana Therapeutics
MRSN
|
65.4 | - | - | $ 3.56 B | USA |
 |
CymaBay Therapeutics
CBAY
|
-33.3 | - | - | $ 3.45 B | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
-2.56 | - | - | $ 384 M | Britain |
 |
Genmab A/S
GMAB
|
2.7 | $ 54.08 | -3.08 % | $ 3.5 B |  Danmark |
 |
Allakos
ALLK
|
-0.000271 | - | - | $ 28.6 M | USA |
 |
Timber Pharmaceuticals
TMBR
|
-0.0202 | - | - | $ 717 K | USA |
 |
Immuron Limited
IMRN
|
-43.1 | $ 0.9 | 2.27 % | $ 208 M |  Australia |
 |
G1 Therapeutics
GTHX
|
-5.82 | - | - | $ 370 M | USA |
 |
Amryt Pharma plc
AMYT
|
-75 | - | - | $ 621 M | Britain |
 |
BioVie
BIVI
|
-0.258 | $ 1.25 | -3.85 % | $ 9.06 M | USA |
 |
Kinnate Biopharma
KNTE
|
-0.674 | - | - | $ 123 M | USA |
 |
Mustang Bio
MBIO
|
2.1 | $ 0.44 | 12.95 % | $ 2.16 M | USA |
|
Cerevel Therapeutics Holdings
CERE
|
-15.5 | - | - | $ 7.29 B | USA |
 |
NexImmune
NEXI
|
-0.173 | - | 70.13 % | $ 4.12 M | USA |
 |
Codexis
CDXS
|
-4.31 | $ 1.0 | -9.91 % | $ 87.1 M | USA |
 |
Theravance Biopharma
TBPH
|
26.7 | $ 17.03 | 0.03 % | $ 857 M |  Cayman-islands |
 |
Compugen Ltd.
CGEN
|
3.32 | $ 2.06 | -3.72 % | $ 192 M |  Israel |
 |
IMV
IMV
|
-3.88 | - | - | $ 13.1 M | Canada |
 |
Sanofi
SNY
|
8.13 | $ 48.23 | 0.22 % | $ 58.9 B |  France |
 |
Karuna Therapeutics
KRTX
|
-23.7 | - | - | $ 12.2 B | USA |
 |
Chimerix
CMRX
|
0.0697 | - | - | $ 756 M | USA |
 |
Atreca
BCEL
|
17.4 | - | -11.76 % | $ 5.79 M | USA |
 |
LogicBio Therapeutics
LOGC
|
-1.39 | - | - | $ 229 M | USA |
 |
RedHill Biopharma Ltd.
RDHL
|
-1.65 K | $ 0.38 | -5.06 % | $ 4.68 B | Israel |
|
89bio
ETNB
|
-2.41 | - | - | $ 1.55 B | USA |
 |
Fusion Pharmaceuticals
FUSN
|
-14.2 | - | - | $ 1.41 B | Canada |
 |
Gritstone Oncology
GRTS
|
-2.57 | - | 0.42 % | $ 213 M | USA |
 |
Harpoon Therapeutics
HARP
|
-0.58 | - | - | $ 763 M | USA |
 |
HOOKIPA Pharma
HOOK
|
0.172 | - | -6.92 % | $ 79.4 M | USA |
 |
Guardion Health Sciences
GHSI
|
0.599 | - | -0.31 % | $ 3.64 M | USA |
 |
Opiant Pharmaceuticals
OPNT
|
19.5 | - | - | $ 109 M | USA |
 |
Akouos
AKUS
|
-1.27 | - | 0.23 % | $ 488 M | USA |
 |
Otonomy
OTIC
|
-1.86 | - | -1.96 % | $ 4.68 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-1.29 | - | 17.91 % | $ 11.1 M | USA |
 |
Seagen
SGEN
|
-45.9 | - | - | $ 42.2 B | USA |
|
Protara Therapeutics
TARA
|
-3.24 | $ 2.44 | -2.59 % | $ 105 M | USA |
 |
Baudax Bio
BXRX
|
-1.67 | - | 0.59 % | $ 63 K | USA |
 |
ChemoCentryx
CCXI
|
-0.721 | - | - | $ 3.74 B | USA |
 |
Avid Bioservices
CDMO
|
-87.3 | - | - | $ 789 M | USA |